Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin and Sitagliptin in Joslin Medalists with Monogenic Diabetes
NCT04409795Phase 3Completed
- Sponsor
- Joslin Diabetes Center
- Start
- Aug 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of liquid metformin (Aspargo Labs) and sitagliptin in type 1 diabetes mellitus (T1D) and monogenic diabetes (2 arms), sponsored by Joslin Diabetes Center. Primary endpoint: Glycated hemoglobin at 6 months. Started Aug 2021; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)sitagliptin
03
Conditions
type 1 diabetes mellitus (T1D)monogenic diabetes
Beyond the preview
Go deeper on NCT04409795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04409795.